Introduction {#sec1}
============

miRNAs are a type of small non-coding RNAs that play roles at post-transcriptional level by sequence-specific binding to the 3′-UTRs of target mRNAs \[[@B1]\]. During the miRNA maturing processing, primary miRNAs (pri-miRNAs) are first synthesized by RNA II polymerase in nucleus. And then, they are converted into precursor miRNAs (pre-miRNAs) by a Drosha--DGCR8 microprocessor complex which is constituted by *DROSHA*, an RNase III superfamily member and its cofactor *DGCR8* \[[@B2]\]. Next, the pre-miRNAs are exported to cytoplasm and converted into mature miRNAs by *DICER*. miRNA genes are deemed to function as both oncogenes and tumor suppressors and their expressions have been confirmed to be associated with varieties of cancers \[[@B3]\]. Hence, imparied miRNA processing caused by the aberrant expression of miRNA biosynthesis genes *DROSHA* or *DGCR8* can noticeably promote the tumorigenesis \[[@B6]\].

As the most prevalent genetic variation, single nucleotide polymorphisms (SNPs) in *DROSHA* and *DGCR8* genes can affect their structure or expression, resulting in incomplete miRNA processing and in turn influence the expression of target genes, thereby acting as risk factor for diseases such as cancer. Thus far, accumulating studies have been concerned with the association between *DROSHA* and *DGCR8* SNPs and the susceptibility to cancer. However, the findings were inconsistent and there was no systematic analysis for *DROSHA* and *DGCR8* SNPs and cancer risk. In the present study, we comprehensively reviewed the eligible studies and analyzed all available data. Our aim is to explore the association of *DROSHA* and *DGCR8* SNPs with cancer risk, supplying clues to researchers for screening novel cancer biomarkers.

Methods {#sec2}
=======

Retrieval strategy {#sec2-1}
------------------

A detailed literature retrieval was performed by two independent investigators (J.W. and Z.L.) for publications regarding the association between *DROSHA* and *DGCR8* polymorphisms and cancer risk. Relevant publications were selected from PubMed and Web of Science using a combination of the following keywords: '*DROSHA*/drosha ribonuclease III/RNase III/*DGCR8*/Digeorge syndrome critical region gene 8/Pasha'; 'SNP/polymorphism/variation/variant'; and 'tumor/cancer/carcinoma/neoplasm', up to 1 January 2018.

Inclusion and exclusion criteria {#sec2-2}
--------------------------------

Eligible publications were selected by the following inclusion criteria: (i) a case--control designed study; (ii) regarding the correlation between *DROSHA* or *DGCR8* polymorphisms and cancer risk. Articles meeting the following criteria were excluded: (i) reviews, letters, or editorials; (ii) duplicate records; (iii) unrelated to cancer or *DROSHA* and *DGCR8* polymorphisms; (iv) no available data to extract.

Data extraction {#sec2-3}
---------------

Data extraction was completed by two independent investigators (J.W. and Z.L.). Basic features obtained from each eligible article were as follows: first author's name, publication year (unpublished collected study year), country, ethnicity, type of cancer, gene, polymorphisms, sample size of cases and controls, genotype distribution, Hardy--Weinberg equilibrium (HWE) in controls, source of control groups (population-based (PB) or hospital-based (HB)), genotyping method, adjusted factors, and quality score. When the article covered multiple stages, data were extracted individually. When the data in eligible articles were unavailable, we tried our best to contact the corresponding authors for original data.

Methodology quality assessment {#sec2-4}
------------------------------

Quality of the selected studies was assessed by two independent reviewers (H.D. and X.F.) according to a study regarding the method for assigning quality scores, which was mentioned in prior meta-analyses \[[@B7],[@B8]\]. Six items were evaluated in the quality assessment scale: (i) the representativeness of the cases; (ii) the source of controls; (iii) the ascertainment of relevant cancers; (iv) the sample size; (v) the quality control of the genotyping methods; (vi) HWE in controls. The quality scores of eligible studies ranged from 0 to 10. Studies with scores less than 5 and HWE disequilibrium were removed from the subsequent analyses.

Statistical analysis {#sec2-5}
--------------------

All statistical analyses in the present study were performed by STATA software, version 11.0 (STATA Corp, College Station, TX, U.S.A.). All statistical tests presented were two-tailed and the *P*-values\<0.05 were regarded as statistically significant, unless highlighted otherwise. And the Bonferroni correction was conducted to justify *P*-values \[[@B40]\]. The HWE for the genotype frequencies of *DROSHA* and *DGCR8* polymorphisms in controls was computed by χ^2^ test. The intensity of the correlations between the *DROSHA* and *DGCR8* polymorphisms and the risk of cancer was estimated by odds ratios (ORs) with its corresponding 95% confidence intervals (95% CIs). Between-study heterogeneity was computed by a χ^2^-based Cochran's *Q*test (significance at *P*\<0.10 and *I^2^* \> 50%). We summarized the results by using fixed effect models \[[@B9]\] when the interstudy heterogeneity was absent, otherwise random effect models \[[@B10]\]. Begg's test and Egger's linear regression analysis were performed to estimate the publication bias statistically \[[@B11],[@B12]\]. *P*\<0.10 was regarded as statistically significant in both Egger's and Begg's test \[[@B8],[@B28]\]. What is more, sensitivity analysis was shown to inspect whether the pooled results were steady after we excluded the outlying studies.

Results {#sec3}
=======

Characteristics of the included studies {#sec3-1}
---------------------------------------

As presented in [Figure 1](#F1){ref-type="fig"}, a total of 148 publications were collected through database search after eliminating the duplicate studies. We eliminated 83 records after browsing the titles and abstracts (40 were functional studies; 12 were reviews or meta-analysis; 9 were not case--control studies; 52 were unrelated to *DROSHA* or *DGCR8* SNPs; 8 were unrelated to cancer; 12 were not correlated with cancer risks). What was more, six studies were excluded by calculating (one for the unavailable data; five for the limited study number of *DROSHA* or *DGCR8* polymorphisms). Moreover, the removal of two records from the subsequent analyses was due to the inconformity of their genotype distributions to HWE (*P*~HWE~\<0.05). Hence, in total, ten case--control studies (from nine citations) containing 4265 cancer cases and 4349 cancer-free controls were involved in our meta-analyses, which were accorded with our inclusion criteria and the evaluation of methodology quality. The characteristics of these involved articles were presented in [Table 1](#T1){ref-type="table"} and the frequency distributions of *DROSHA* and *DGCR8* polymorphisms genotype were shown in [Table 2](#T2){ref-type="table"}. In summary obtained from ten eligible case--control studies, seven SNPs of *DROSHA* or *DGCR8* genes were investigated in the eventual analysis. According to the SNPs selection criteria mentioned in eligible studies \[[@B2],[@B14]\], we found that none of these seven SNPs were in strong linkage disequilibrium (*r^2^* ≥ 0.8). In *DROSHA*, the analyzed SNPs were rs10719 T/C, rs6877842 G/C, rs2291109 A/T, rs642321 C/T; in *DGCR8*, the analyzed SNPs are rs3757 G/A, rs417309 G/A, rs1640299 T/G ([Figure 2](#F2){ref-type="fig"}).

![The flow chart of identification for studies included in the meta-analysis](bsr-38-bsr20180072-g1){#F1}

###### A forest plot of the *DROSHA* and *DGCR8* SNPs associated with cancer risk

((a) DROSHA rs10719 in the ethnicity subgroup analysis; (b) DROSHA rs6877842 in the cancer type subgroups; (c) DGCR8 rs417309 under allelic model: A compared with G).
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###### The main features of enrolled studies

  Ref. no.   Year   Country   Ethnicity   Sample size   Source of controls   Genotyping method   Adjusted factors    Quality score                                                                Citation   
  ---------- ------ --------- ----------- ------------- -------------------- ------------------- ------------------- ---------------------------------------------------------------------------- ---------- ------------
  1          2010   Korean    Asian       93            93                   HB                  MS                  NM                                                                           5.5        \[[@B15]\]
  2          2013   China     Asian       878           900                  PB                  Taqman              Age and residential area                                                     7.5        \[[@B2]\]
  3          2013   China     Asian       914           967                  PB                  Taqman              Age and residential area                                                     7.5        \[[@B2]\]
  4          2013   China     Asian       685           730                  HB                  Taqman              Age, sex, and smoking status                                                 7          \[[@B16]\]
  5          2013   America   Caucasian   277           278                  PB                  SNPlex technology   Age, sex, ethnicity, and county of residence                                 7.5        \[[@B14]\]
  6          2015   Korean    Asian       408           400                  HB                  PCR-RFLP            Age, gender, hypertension, diabetes mellitus                                 7          \[[@B24]\]
  7          2015   Polish    Caucasian   135           170                  HB                  Taqman              NM                                                                           7.5        \[[@B25]\]
  8          2016   Polish    Caucasian   100           100                  NM                  Taqman              NM                                                                           6          \[[@B13]\]
  9          2016   Korean    Asian       147           209                  HB                  PCR-RFLP            Age, gender, hypertension, diabetes mellitus, drinking status, and smoking   7          \[[@B26]\]
  10         2017   China     Asian       628           502                  HB                  HRM                 Age, sex, region, smoking status, and drinking status                        7          \[[@B27]\]

Abbreviations: HRM, high-resolution melting; MS, sequenome MS-based genotyping assay; PCR-RFLP, polymerase chain reaction-restriction fragment length polymorphism; NM, not mentioned.

###### Genotype frequency distributions of DROSHA and DGCR8 SNPs in included studies

  Ref. No.   Year   Cancer type                Gene     SNPs^1^      Sample size   Case   Control   *P*~HWE~   MAF in controls (Global MAF^4^)   Included in meta-analysis                                             
  ---------- ------ -------------------------- -------- ------------ ------------- ------ --------- ---------- --------------------------------- --------------------------- ----- ----- ------------- --------------- -------
  1          2010   Lung cancer                DROSHA   rs6877842    93            93     81        11         1                                 84                          8     1     0.136         0.054 (0.138)   Yes
                                                        (G \> C)                                                                                                                                                       
                    Lung cancer                DROSHA   rs10719      97            97     59        29         9                                 52                          38    7     0.987         0.268 (0.483)   Yes
                                                        (T \> C)                                                                                                                                                       
                    Lung cancer                DGCR8    rs3757       94            90     60        27         7                                 60                          24    6     0.114         0.200 (0.182)   Yes
                                                        (G \> A)                                                                                                                                                       
                    Lung cancer                DGCR8    rs417309     98            97     90        8          0                                 88                          9     0     0.632         0.046 (0.043)   Yes
                                                        (G \> A)                                                                                                                                                       
                    Lung cancer                DGCR8    rs1640299    98            97     58        33         7                                 52                          40    5     0.444         0.258 (0.381)   Yes
                                                        (T \> G)                                                                                                                                                       
  2          2013   Breast cancer              DROSHA   rs10719      847           878    433       346        68                                463                         353   62    0.635         0.272 (0.483)   Yes
                                                        (T \> C)                                                                                                                                                       
                    Breast cancer              DROSHA   rs17409893   849           885    527       287        35                                575                         276   34    0.902         0.194 (0.222)   No^3^
                                                        (A \> G)                                                                                                                                                       
                    Breast cancer              DROSHA   rs2291109    858           886    552       273        33                                535                         306   45    0.884         0.223 (0.061)   Yes
                                                        (A \> T)                                                                                                                                                       
                    Breast cancer              DROSHA   rs642321     854           883    212       423        219                               231                         433   219   0.571         0.493 (0.322)   Yes
                                                        (C \> T)                                                                                                                                                       
                    Breast cancer              DGCR8    rs1640299    849           891    465       330        54                                476                         357   58    0.412         0.265 (0.381)   Yes
                                                        (T \> G)                                                                                                                                                       
                    Breast cancer              DGCR8    rs417309     860           893    771       89         0                                 826                         67    0     0.244         0.038 (0.043)   Yes
                                                        (G \> A)                                                                                                                                                       
                    Breast cancer              DGCR8    rs720012     867           891    225       425        217                               240                         451   200   0.668         0.478 (0.221)   No^3^
                                                        (G \> A)                                                                                                                                                       
                    Breast cancer              DGCR8    rs720014     836           880    542       264        30                                555                         287   38    0.907         0.206 (0.183)   No^3^
                                                        (T \> C)                                                                                                                                                       
  3          2013   Breast cancer              DROSHA   rs2291109    899           957    563       296        40                                625                         298   34    0.835         0.191 (0.061)   Yes
                                                        (A \> T)                                                                                                                                                       
                    Breast cancer              DGCR8    rs417309     901           960    830       68         3                                 910                         49    1     0.687         0.027 (0.043)   Yes
                                                        (G \> A)                                                                                                                                                       
  4          2013   Bladder cancer             DROSHA   rs2291109    685           730    421       228        36                                419                         280   31    0.062         0.234 (0.061)   Yes
                                                        (A \> T)                                                                                                                                                       
                    Bladder cancer             DROSHA   rs10719      684           727    352       278        54                                413                         275   39    0.437         0.243 (0.483)   Yes
                                                        (T \> C)                                                                                                                                                       
                    Bladder cancer             DROSHA   rs642321     685           730    197       326        162                               176                         371   183   0.655         0.505 (0.322)   Yes
                                                        (C \> T)                                                                                                                                                       
  5          2013   Renal cell carcinoma       DROSHA   rs10719      252           246    161       75         16                                155                         76    15    0.177         0.215 (0.483)   Yes
                                                        (T \> C)                                                                                                                                                       
                    Renal cell carcinoma       DROSHA   rs6877842    275           278    200       65         10                                204                         65    9     0.185         0.149 (0.138)   Yes
                                                        (G \> C)                                                                                                                                                       
                    Renal cell carcinoma       DGCR8    rs3757       276           278    163       102        11                                162                         102   14    0.688         0.234 (0.182)   Yes
                                                        (G \> A)                                                                                                                                                       
                    Renal cell carcinoma       DGCR8    rs417309     277           278    243       30         4                                 243                         34    1     0.87          0.065 (0.043)   Yes
                                                        (G \> A)                                                                                                                                                       
                    Renal cell carcinoma       DGCR8    rs1640299    277           278    61        151        65                                75                          136   67    0.729         0.486 (0.381)   Yes
                                                        (T \> G)                                                                                                                                                       
  6          2015   Colorectal cancer          DROSHA   rs10719      408           400    224       154        30                                211                         168   21    0.09          0.263 (0.483)   Yes
                                                        (T \> C)                                                                                                                                                       
  7          2015   Laryngeal cancer           DROSHA   rs6877842    128           170    73        49         6                                 76                          79    15    0.384         0.321 (0.138)   Yes
                                                        (G \> C)                                                                                                                                                       
                    Laryngeal cancer           DGCR8    rs417309     112           170    67        32         13                                116                         46    8     0.227         0.182 (0.043)   Yes
                                                        (G \> A)                                                                                                                                                       
                    Laryngeal cancer           DGCR8    rs1640299    113           170    60        47         6                                 61                          93    16    **0.021**     0.368 (0.381)   No^2^
                                                        (T \> G)                                                                                                                                                       
                    Laryngeal cancer           DGCR8    rs3757       122           170    29        89         4                                 36                          119   15    **\<0.001**   0.438 (0.182)   No^2^
                                                        (G \> A)                                                                                                                                                       
  8          2016   Laryngeal cancer           DROSHA   rs6877842    100           100    60        35         5                                 44                          47    9     0.476         0.325 (0.138)   Yes
                                                        (G \> C)                                                                                                                                                       
                    Laryngeal cancer           DGCR8    rs417309     100           100    60        28         12                                69                          27    4     0.516         0.175 (0.043)   Yes
                                                        (G \> A)                                                                                                                                                       
                    Laryngeal cancer           DGCR8    rs1640299    100           100    52        42         6                                 36                          55    9     0.062         0.365 (0.381)   Yes
                                                        (T \> G)                                                                                                                                                       
  9          2016   Hepatocellular carcinoma   DROSHA   rs10719      147           209    81        53         13                                110                         88    11    0.215         0.263 (0.483)   Yes
                                                        (T \> C)                                                                                                                                                       
                    Hepatocellular carcinoma   DROSHA   rs6877842    147           209    138       9          0                                 200                         9     0     0.75          0.022 (0.138)   Yes
                                                        (G \> C)                                                                                                                                                       
  10         2017   Gastirc cancer             DROSHA   rs10719      628           502    314       257        57                                248                         205   49    0.487         0.302 (0.483)   Yes
                                                        (T \> C)                                                                                                                                                       

The results were in bold if *P*\<0.05. Abbreviations: MAF, minor allele frequency; *P*~HWE~, the *P*-value for HWE in control groups.

^1^, The ancestral alleles were referenced in the NCBI database.

^2^, Excluded due to the SNP not being in accordance with HWE.

^3^, Excluded due to the limited number for this locus;

^4^, The global MAFs were referenced in the NCBI database.

Quantitative data synthesis of seven SNPs in *DROSHA* and *DGCR8* genes {#sec3-2}
-----------------------------------------------------------------------

### Four SNPs in DROSHA {#sec3-2-1}

First, all eligible articles were summarized to evaluate the correlation strength of each *DROSHA* SNP with the risk of overall cancer. However, these four SNPs (rs10719 T/C, rs6877842 G/C, rs642321 C/T, and rs2291109 A/T) did not manifest any significant associations with cancer risk in any genetic models ([Table 3](#T3){ref-type="table"}). Due to the existence of interstudy heterogeneity, stratified analyses were performed.

###### Meta-analysis of the association between DROSHA and DGCR8 polymorphisms and cancer risk

                                      Heterozygote compared with homozygote wild   Homozygote variant compared with homozygote wild   Dominant model   Recessive model     Allelic model                                                                                                                                                                         
  ------------------------------- --- -------------------------------------------- -------------------------------------------------- ---------------- ------------------- ----------------------- ------ ------------------- ---------------------- ------ ------------------- ----------------------- ------ ------------------------- ----------------------- ------
  **DROSHA rs10719 (T \> C)**     7   0.934                                        1.004 (0.904--1.117)                               0.2              0.055               1.214 (0.996--1.480)    0.0    0.502               1.035 (0.936--1.145)   10.5   0.053               1.210 (0.998--1.467)    0.0    0.179                     1.056 (0.975--1.145)    0
  Ethnicity                                                                                                                                                                                                                                                                                                                                                      
  Asian                           6   0.874                                        1.009 (0.904--1.126)                               15.6             **0.048** (0.336)   1.230 (1.001--1.511)    0.0    0.449               1.041 (0.938--1.157)   10.5   **0.04** (0.336)    1.223 (1.002--1.494)    0.0    0.154                     1.062 (0.978--1.154)    0
  Caucasian                       1   0.796                                        0.950 (0.645--1.400)                               NA               0.944               1.027 (0.491--2.148)    NA     0.838               0.963 (0.668--1.387)   NA     0.907               1.044 (0.504--2.161)    NA     0.904                     0.981 (0.725--1.329)    NA
  Source of controls                                                                                                                                                                                                                                                                                                                                             
  HB                              5   0.905                                        0.992 (0.869--1.132)                               30.1             0.071               1.257 (0.981--1.610)    0      0.643               1.030 (0.908--1.169)   27.2   0.061               1.259 (0.989--1.602)    0      0.25                      1.060 (0.0960--1.172)   16.7
  PB                              2   0.767                                        1.027 (0.861--1.225)                               0                0.396               1.142 (0.822--1.588)    0.0    0.616               1.044 (0.883--1.234)   0      0.463               1.128 (0.818--1.555)    0.0    0.398                     1.049 (0.918-1.199)     0
  **DROSHA rs6877842 (G \> C)**   5   0.174                                        0.841 (0.655--1.079)                               39.3             0.101               0.627 (0.358--1.096)    0.0    0.358^1^            0.839 (0.577--1.220)   50.7   0.218               0.706 (0.406--1.228)    0.0    0.073                     0.832 (0.680--1.017)    48.2
  Ethnicity                                                                                                                                                                                                                                                                                                                                                      
  Asian                           2   0.292                                        1.438 (0.732--2.824)                               0                0.98                1.037 (0.064--16.860)   NA     0.303               1.414 (0.731--2.735)   0.0    1                   1.000 (0.062--16.230)   NA     0.326                     1.372 (0.731--2.576)    0
  Caucasian                       3   0.059                                        0.772 (0.590--1.010)                               47.1             0.094               0.613 (0.346--1.087)    27.5   0.125^1^            0.716 (0.467--1.097)   61.1   0.21                0.697 (0.396--1.225)    0.0    0.123^1^                  0.762 (0.540--1.076)    60.1
  Source of controls                                                                                                                                                                                                                                                                                                                                             
  HB                              3   0.395                                        0.845 (0.574--1.245)                               44.3             0.103               0.460 (0.181--1.169)    0      0.88^1^             0.953 (0.506--1.793)   52.5   0.194               0.545 (0.218--1.361)    0      0.155                     0.796 (0.581--1.090)    48.0
  PB                              1   0.922                                        1.020 (0.687--1.514)                               NA               0.79                1.133 (0.451--2.848)    NA     0.862               1.034 (0.710--1.505)   NA     0.797               1.128 (0.451--2.820)    NA     0.807                     1.042 (0.750--1.447)    NA
  NM                              1   0.043                                        0.546 (0.304--0.981)                               NA               0.129               0.407 (0.128--1.300)    NA     0.024               0.524 (0.299--0.919)   NA     0.274               0.532 (0.172--1.648)    NA     0.026                     0.603 (0.387--0.941)    NA
  Cancer type                                                                                                                                                                                                                                                                                                                                                    
  Laryngeal cancer                2   **0.008** (0.56)                             0.604 (0.417--0.875)                               0                **0.022** (0.154)   0.413 (0.193--0.881)    0.0    **0.002 (0.014)**   0.573 (0.401--0.819)   0.0    0.081               0.518 (0.247--1.084)    0.0    **0.002 (0.014)**         0.638 (0.481--0.847)    0.0
  Lung cancer                     1   0.469                                        1.426 (0.546--3.726)                               NA               0.98                1.037 (0.064--16.860)   NA     0.488               1.383 (0.553--3.458)   NA     1                   1.000 (0.062--16.230)   NA     0.52                      1.323 (0.565--3.096)    NA
  Hepatocellular carcinoma        1   0.443                                        1.449 (0.561--3.744)                               NA               NA                  NA                      NA     0.443               1.449 (0.561--3.744)   NA     NA                  NA                      NA     0.45                      1.435 (0.563--3.660)    NA
  Renal cell carcinoma            1   0.922                                        1.020 (0.687--1.514)                               NA               0.79                1.133 (0.451--2.848)    NA     0.862               1.034 (0.710--1.505)   NA     0.797               1.128 (0.451--2.820)    NA     0.807                     1.042 (0.750--1.447)    NA
  **DROSHA rs642321 (C \> T)**    2   0.576                                        0.918 (0.682--1.237)                               0.0              0.672^1^            0.934 (0.683--1.279)    60.5   0.603^1^            0.923 (0.681--1.250)   72.2   0.911               0.991 (0.843--1.165)    0      0.665^1^                  0.965 (0.821--1.134)    62.3
  **DROSHA rs2291109 (A \> T)**   3   0.389^1^                                     0.922 (0.765--1.110)                               58.8             0.92                1.014 (0.771--1.333)    44.7   0.469^1^            0.932 (0.770--1.128)   63.8   0.746               1.046 (0.798--1.371)    37.4   0.606^1^                  0.958 (0.815--1.126)    64.6
  Cancer type                                                                                                                                                                                                                                                                                                                                                    
  Breast cancer                   2   0.851^1^                                     0.977 (0.770--1.240)                               64.9             0.899^1^            0.962 (0.530--1.747)    69.2   0.859^1^            0.975 (0.738--1.289)   76.4   0.909^1^            0.971 (0.580--1.624)    59.6   0.871^1^                  0.978 (0.752--1.272)    81
  Bladder cancer                  1   0.062                                        0.810 (0.650--1.011)                               NA               0.57                1.156 (0.702--1.903)    NA     0.12                0.845 (0.683--1.045)   NA     0.373               1.251 (0.765--2.046)    NA     0.332                     0.917 (0.768--1.093)    NA
  Source of controls                                                                                                                                                                                                                                                                                                                                             
  PB                              2   0.851^1^                                     0.977 (0.770--1.240)                               64.9             0.899^1^            0.962 (0.530--1.747)    69.2   0.859^1^            0.975 (0.738--1.289)   76.4   0.909^1^            0.971 (0.580--1.624)    59.6   0.871^1^                  0.978 (0.752--1.272)    81
  HB                              1   0.062                                        0.810 (0.650--1.011)                               NA               0.57                1.156 (0.702--1.903)    NA     0.12                0.845 (0.683--1.045)   NA     0.373               1.251 (0.765--2.046)    NA     0.332                     0.917 (0.768--1.093)    NA
  **DGCR8 rs3757 (G \> A)**       2   0.892                                        1.022 (0.750--1.391)                               0.0              0.741               0.894 (0.460--1.737)    0      0.974               1.005 (0.748--1.350)   0      0.715               0.885 (0.460--1.704)    0      0.913                     0.986 (0.772--1.260)    0.0
  **DGCR8 rs417309 (G \> A)**     6   **0.012** (0.084)                            1.282 (1.057--1.555)                               0.0              **0.001 (0.007)**   3.169 (1.634--6.146)    0      **0.001 0.007)**    1.365 (1.131--1.647)   0      **0.001 (0.007)**   3.026 (1.574--5.817)    0      **6.90E-05 (4.83E-04)**   1.423 (1.196--1.693)    0.0
  Ethnicity                                                                                                                                                                                                                                                                                                                                                      
  Asian                           3   **0.004 (0.028)**                            1.420 (1.115--1.809)                               0.0              0.303               3.289 (0.341--31.682)   NA     **0.003 0.021)**    1.435 (1.129--1.825)   0      0.314               3.204 (0.333--30.856)   NA     **0.003 (0.021)**         1.429 (1.131--1.806)    0.0
  Caucasian                       3   0.699                                        1.066 (0.772--1.472)                               0.0              **0.001 (0.007)**   3.157 (1.579--6.310)    0      0.133               1.260 (0.932--1.704)   0      **0.002 (0.014)**   3.009 (1.520--5.954)    0      **0.009** (0.063)         1.415 (1.092--1.834)    2.7
  Cancer type                                                                                                                                                                                                                                                                                                                                                    
  laryngeal cancer                2   0.387                                        1.199 (0.795--1.810)                               0.0              **0.003 (0.021)**   3.059 (1.474--6.351)    0      0.05                1.460 (1.000--2.131)   0      **0.004 (0.028)**   2.895 (1.410--5.945)    0      **0.003 (0.021)**         1.604 (1.176--2.188)    0.0
  Breast cancer                   2   **0.003 (0.021)**                            1.465 (1.141--1.881)                               0.0              0.303               3.289 (0.341--31.682)   NA     **0.002 (0.014)**   1.481 (1.155--1.898)   0      0.314               3.204 (0.333--30.856)   NA     **0.002 (0.014)**         1.473 (1.157--1.876)    0.0
  Lung cancer                     1   0.783                                        0.869 (0.321--2.355)                               NA               NA                  NA                      NA     0.783               0.869 (0.321--2.355)   NA     NA                  NA                      NA     0.788                     0.875 (0.330--2.316)    NA
  Renal cell carcinoma            1   0.638                                        0.882 (0.523--1.487)                               NA               0.217               4.000 (0.444--36.046)   NA     0.91                0.971 (0.587--1.609)   NA     0.212               4.059 (0.451--36.544)   NA     0.797                     1.064 (0.664--1.705)    NA
  Source of controls                                                                                                                                                                                                                                                                                                                                             
  PB                              3   **0.012** (0.084)                            1.333 (1.065--1.669)                               33.7             0.107               3.652 (0.755--17.659)   0      **0.006 (0.042)**   1.364 (1.093--1.704)   12.4   **0.036 (0.252)**   2.659 (1.064--6.643)    NA     0.059                     1.434 (0.986--2.085)    14.7
  HB                              2   0.648                                        1.117 (0.694--1.799)                               0.0              **0.029 (0.203)**   2.813 (1.109--7.135)    NA     0.243               1.302 (0.836--2.030)   0      0.108               3.635 (0.752--17.564)   0      **0.003 (0.021)**         1.377 (1.111--1.707)    0.0
  NM                              1   0.585                                        1.193 (0.634--2.243)                               NA               0.04                3.450 (1.057--11.265)   NA     0.184               1.484 (0.828--2.658)   NA     0.047               3.273 (1.018--10.523)   NA     0.04                      1.656 (1.022--2.684)    NA
  **DGCR8 rs1640299 (T \> G)**    4   0.508^1^                                     0.895 (0.645--1.243)                               60.2             0.988               0.998 (0.751--1.325)    0      0.494               0.898 (0.659--1.223)   59.1   0.786               0.965 (0.745--1.249)    0      0.48                      0.959 (0.852--1.078)    34.6
  Ethnicity                                                                                                                                                                                                                                                                                                                                                      
  Asian                           2   0.403                                        0.923 (0.766--1.113)                               0.0              0.91                0.979 (0.674--1.420)    0      0.434               0.931 (0.778--1.114)   0      0.952               1.011 (0.703--1.455)    0      0.545                     0.957 (0.829--1.104)    0.0
  Caucasian                       2   0.769^1^                                     0.870 (0.344--2.202)                               85.3             0.726^1^            0.853 (0.350--2.076)    57.3   0.713^1^            0.844 (0.342--2.085)   85.6   0.656               0.920 (0.638--1.328)    0      0.576^1^                  0.864 (0.517--1.443)    77.9
  Source of controls                                                                                                                                                                                                                                                                                                                                             
  PB                              2   0.643^1^                                     1.086 (0.767--1.537)                               60.2             0.788               1.043 (0.770--1.412)    0      0.694^1^            1.063 (0.785--1.439)   53.5   0.831               0.971 (0.738--1.276)    0      0.974                     0.998 (0.879--1.133)    0.0
  HB                              1   0.32                                         0.740 (0.408--1.339)                               NA               0.712               1.255 (0.375--4.197)    NA     0.433               0.797 (0.452--1.405)   NA     0.565               1.415 (0.433--4.623)    NA     0.682                     0.908 (0.574---1.438)   NA
  NM                              1   0.033                                        0.529 (0.295--0.949)                               NA               0.175               0.462 (0.151--1.410)    NA     0.023               0.519 (0.295--0.915)   NA     0.424               0.645 (0.221--1.886)    NA     0.042                     0.643 (0.421--0.984)    NA

The results are in bold if *P*\<0.05. Abbreviation: *P*~corr~, *P*-values after Bonferroni correction.

^1^, *P* was calculated by random model.

In subgroup analyses, rs10719 and rs6877842 SNPs were analyzed in 'ethnicity' subgroup; the rs6877842 and rs2291109 SNPs were analyzed in 'cancer type' subgroup; rs10719, rs6877842, and rs2291109 SNPs were analyzed in 'source of controls' subgroup. For rs10719 T/C SNP, its homozygote variant genotype and recessive models were correlated with an elevated cancer risk in Asian (CC compared with TT: OR = 1.230, 95% CI = 1.001--1.511, *P*=0.048; CC + CT compared with TT: OR = 1.223, 95% CI = 1.002--1.494, *P*=0.048, [Table 3](#T3){ref-type="table"}). For rs6877842 G/C SNP, its heterozygote model had strong correlation with a reduced risk of laryngeal cancer (CG compared with GG: OR = 0.413, 95% CI = 0.193--0.881, *P*=0.022, [Table 3](#T3){ref-type="table"}) and its homozygote variant genotype, dominant and allelic models had moderate associations with a descending risk of laryngeal cancer (CC compared with GG: OR = 0.604, 95% CI = 0.417--0.875, *P*=0.008; CC compared with CG + GG: OR = 0.573, 95% CI = 0.401--0.819, *P*=0.002; C compared with G: OR = 0.638, 95% CI = 0.481--0.847, *P*=0.002, [Table 3](#T3){ref-type="table"}). For rs2291109 polymorphism, however, the correlations with cancer risk were not elucidated in any stratified analyses.

### Three SNPs in DGCR8 {#sec3-2-2}

We evaluated the correlation strength of the polymorphisms in *DROSHA* gene with cancer risk, based on the entire population. The rs417309 G/A SNP was demonstrated to be associated with an increased risk of cancer. Strong associations of rs417309 were found in homozygote variant genotype and recessive models (AA compared with GG: OR = 3.169, 95% CI = 1.634--6.146, *P*=0.001; AA + AG compared with GG: OR = 3.026, 95% CI = 1.574--5.817, *P*=0.001). Correlations of rs417309 could also be found in other three models (AG compared with GG: OR = 1.282, 95% CI = 1.057--1.555, *P*=0.012; AA compared with AG + GG: OR = 1.365, 95% CI = 1.131--1.647, *P*=0.001; A compared with G: OR = 1.423, 95% CI = 1.196--1.693, *P*\<0.001, [Table 3](#T3){ref-type="table"}). Associations of the rs3757 G/A and rs1640299 T/G SNPs with cancer risk were not illustrated in primary analyses.

In stratified analyses, rs417309 and rs1640299 SNPs were analyzed in 'ethnicity' and 'source of controls' subgroups; the rs417309 SNP was also analyzed in 'cancer type' subgroup. For rs417309 G/A SNP, its associations were observed in every subgroup (including: Asian population, Caucasian population; laryngeal cancer, breast cancer; PB, HB). Amongst all significant associations in subgroup analyses, only strong associations were reported below. In Caucasian subgroup, strong correlations were indicated in homozygote variant genotype and recessive models (AA compared with GG: OR = 3.169, 95% CI = 1.634--6.146, *P*=0.001; AA + AG compared with GG: OR = 3.026, 95% CI = 1.574--5.817, *P*=0.001). In laryngeal cancer subgroup, strong relationships were observed in homozygote variant genotype and recessive models (AA compared with GG: OR = 3.169, 95% CI = 1.634--6.146, *P*=0.001; AA + AG compared with GG: OR = 3.026, 95% CI = 1.574--5.817, *P*=0.001), When the control groups were PB, the recessive type (AA + AG) showed a strong relationship with an increased risk of cancer, compared with the wild-type GG (OR = 1.604, 95% CI = 1.176--2.188, *P*=0.003). When the controls groups were HB, the homozygote variant model of rs417309 presented a strong correlation with cancer risk (AA compared with GG: OR = 2.813, 95% CI = 1.109--7.135, *P*=0.029, [Table 3](#T3){ref-type="table"}). For rs1640299 T/G polymorphism, however, no significant relationship was found in any subgroup analyses.

### Sensitivity analysis {#sec3-2-3}

Sensitivity analyses were conducted to calculate the effect of individual study on the merged findings by evaluating the sensitivity before and after eliminating each study from our meta-analysis (Supplementary Table S1). For rs417309 SNP, it was no longer statistically significant after we removed the study conducted by Jiang et al. (Supplementary Table S1) \[[2](#T4){ref-type="table"}\].

### Publication bias {#sec3-2-4}

Begg's and Egger's tests were performed to evaluate the potential publication bias. The publication bias was revealed in the heterozygote genotype and the dominant models of rs10719 SNP in both Begg's and Egger's tests, for *P*\<0.1 ([Table 4](#T4){ref-type="table"}). This might be due to the language bias, the lack of publications with opposing results, and/or the inflated estimates caused by a deficient methodological design in smaller studies \[[@B1]\].

###### The results of Begg's and Egger's tests for the publication bias

                                                     Begg's test   Egger's test            
  -------------------------------------------------- ------------- -------------- -------- -----------
  **DROSHA rs10719 (T \> C)**                                                              
  Heterozygote compared with homozygote wild         −2.250        **0.024**      −3.030   **0.029**
  Homozygote variant compared with homozygote wild   0.450         0.652          0.300    0.774
  Dominant model                                     −1.950        **0.051**      −2.340   **0.066**
  Recessive model                                    0.560         0.573          1.100    0.332
  Allelic model                                      −0.750        0.453          −1.330   0.241
  **DROSHA rs6877842 (G \> C)**                                                            
  Heterozygote compared with homozygote wild         −0.490        0.624          0.620    0.581
  Homozygote variant compared with homozygote wild   0.000         1.000          0.020    0.988
  Dominant model                                     0.000         1.000          0.500    0.650
  Recessive model                                    0.000         1.000          0.030    0.976
  Allelic model                                      0.000         1.000          0.740    0.511
  **DROSHA rs642321 (C \> T)**                                                             
  Heterozygote compared with homozygote wild         −1.000        0.317          NA       NA
  Homozygote variant compared with homozygote wild   −1.000        0.317          NA       NA
  Dominant model                                     −1.000        0.317          NA       NA
  Recessive model                                    −1.000        0.317          NA       NA
  Allelic model                                      −1.000        0.317          NA       NA
  **DROSHA rs2291109 (A \> T)**                                                            
  Heterozygote compared with homozygote wild         −1.570        0.117          −1.270   0.426
  Homozygote variant compared with homozygote wild   0.520         0.602          0.560    0.673
  Dominant model                                     −0.520        0.602          −0.830   0.558
  Recessive model                                    0.520         0.602          0.870    0.545
  Allelic model                                      −0.520        0.602          −0.430   0.741
  **DGCR8 rs3757 (G \> A)**                                                                
  Heterozygote compared with homozygote wild         1.000         0.317          NA       NA
  Homozygote variant compared with homozygote wild   1.000         0.317          NA       NA
  Dominant model                                     1.000         0.317          NA       NA
  Recessive model                                    1.000         0.317          NA       NA
  Allelic model                                      1.000         0.317          NA       NA
  **DGCR8 rs417309 (G \> A)**                                                              
  Heterozygote compared with homozygote wild         −0.940        0.348          −2.150   0.098
  Homozygote variant compared with homozygote wild   0.680         0.497          1.460    0.282
  Dominant model                                     −1.320        0.188          −1.460   0.219
  Recessive model                                    0.680         0.497          1.710    0.230
  Allelic model                                      −0.190        0.851          −1.320   0.258
  **DGCR8 rs1640299 (T \> G)**                                                             
  Heterozygote compared with homozygote wild         −0.680        0.497          −0.540   0.644
  Homozygote variant compared with homozygote wild   0.000         1.000          −0.560   0.635
  Dominant model                                     −0.680        0.497          −0.560   0.634
  Recessive model                                    0.000         1.000          −0.070   0.949
  Allelic model                                      −0.680        0.497          −0.880   0.471

The results are in bold if *P*\<0.1. Abbreviation: NA, not available.

Discussion {#sec4}
==========

In the present study, total seven SNPs in *DROSHA* and *DGCR8* genes were comprehensively reviewed and analyzed to estimate their associations with the risk of overall cancer. Of these seven SNPs, four (rs6877842, rs642321, rs2291109, rs3757) were analyzed for the first time. Our findings indicated that rs417309 SNP of *DGCR8* might facilitate the cancerogenesis. Moreover, correlations with cancer risk could also be observed in stratified analyses of *DROSHA* rs10719, rs6877842 SNPs and *DGCR8* rs417309 SNP. No associations were revealed amongst other studied SNPs.

Polymorphisms in DROSHA {#sec4-1}
-----------------------

As an RNase III superfamily member, *DROSHA* initiates miRNA processing by converting pri-miRNA into pre-miRNA. Current studies have indicated the role of *DROSHA* on the development of several sorts of cancers such as laryngeal, bladder, lung, and so on \[[@B13]\]. And mounting studies have focussed on the correlations of *DROSHA* polymorphisms with cancer risk. Based on our analyses, the significant associations with cancer risk could be observed in rs10719 and rs6877842 SNPs.

Regarding rs10719 T/C polymorphism, we presented significant associations between rs10719 SNP (CC or TC + CC genotypes) and cancer risk in Asian population. Located in the *DROSHA* 3′-UTR region, the T to C substitution of rs10719 disrupted an hsa-*miR-27b* binding site, which was identified by luciferase reported gene assays, leading to an overexpression of *DROSHA* gene at the post-transcriptional level \[[@B16]\]. The overexpression of *DROSHA* caused by rs10719-C allele was elucidated to facilitate the proliferation and inhibit apoptosis of cancer cells \[[@B17]\], which was in-line with our meta-analysis findings. The meta-analysis of rs10719 analyzed six case--control studies, five of which, however, were inconsistent with our study. From our viewpoint, this phenomenon might be owing to the limitation of sample size, diversity of cancer type, and/or complexity of environmental factors. Hence, further investigations that concentrate on rs10719 SNP are extremely needed to obtain more credible results.

As for rs6877842 G/C polymorphism, strong/moderate correlations with the laryngeal cancer could be observed in every genetic model except recessive model and the rs687742-C allele manifested a protective effect on laryngeal cancer. Located in the promoter region of DROSHA, the rs6877842 SNP might influence the expression level of *DROSHA* by altering the transcription factor binding sites, which was forecasted by a bioinformatics website '<https://snpinfo.niehs.nih.gov/>', thus inhibiting the laryngeal cancer development. Our study analyzed five case--control studies on different cancers: laryngeal (two), lung (one), hepatocellular (one), and renal cell carcinoma (one). Interestingly, the association of rs6877842 SNP could only be observed in laryngeal cancer subgroup, rather than in the overall cancer analysis. And the between-study heterogeneity was absent after we conducted the 'cancer type' subgroup. Thus, it is reasonable to suggest that the effect of rs6877842 SNP on overall cancer susceptibility could be masked by the existence of heterogeneity deriving from different types of cancer. Further investigations on this SNP are in demand to verify our speculation.

Polymorphisms in DGCR8 {#sec4-2}
----------------------

The Drosha--DGCR8 microprocessor complex could mediate the biogenesis from pri-miRNA to pre-miRNA, whereas neither Drosha or recombinant DGCR8 alone is active in this processing, suggesting that both the proteins are indispensable in miRNA maturing processing \[[@B20]\]. *DGCR8* are also referred to as Pasha, stabilizes Drosha by protein--protein, and takes charge of recognizing ssRNA and dsRNA structures \[[@B21]\]. Studies have revealed the up-regulation of *DGCR8* expression in various cancers \[[@B22],[@B23]\]. And accumulating researches have focussed on the associations between the *DGCR8* polymorphisms and cancer risk.

The rs417309 G/A polymorphism was the most extensively investigated one amongst *DGCR8* SNPs, and the rs417309-A allele was strongly associated with an elevated cancer susceptibility. Based on the bioinformatics website prediction '<https://snpinfo.niehs.nih.gov/>', rs417909 SNP was located at miRNA-binding sites (*miR-106b* and *miR-579*) in 3′-UTR region of DGCR8. The risk allele rs417309-A could elevate *DGCR8* expression level, probably through interrupting miRNA binding \[[@B2]\], thus facilitating the cancer development. The meta-analysis of rs417309 SNP involved six case--control studies. Two of them, however, showed no association with cancer risk. Thus, further investigations concerned with rs417309 SNP remain in strong demand for identifying this potential cancer biomarker.

Limitations in our meta-analysis must be recognized. First, only eligible articles published in English were incorporated in our study, which might result in certain publication bias. Second, studies of *DROSHA* and *DGCR8* polymorphisms on cancer predisposition field remain emerging, which resulted in limited number of the relevant investigations. Third, we did not analyze the association of polymorphisms in other miRNA-machinery genes, which were listed in [Table 5](#T5){ref-type="table"} including: *DICER1, XPO5, RAN, TARBP2, AGO2, HIWI, GEMIN3*, and *GEMIN4*. Because their study number was limited or because they have already been analyzed in other meta-analyses.

###### Reviews of the other miRNA-machinery gene polymorphisms studied in regard to cancer risk

  Gene     SNP                   Position        Cancer type                                        Citation
  -------- --------------------- --------------- -------------------------------------------------- -----------------------------------------------
  *XPO5*   rs11077 (A \> G)      3′-UTR          EC, BC, CRC, TC, RCC, bladder, and larynx cancer   \[[@B2],[@B14],[@B15],[@B25],[@B29]\]
  *RAN*    rs14035 (C \> T)      3′-UTR          RCC, LC, CRC, EC, GC, OC, and larynx cancer        \[[@B14],[@B15],[@B24],[@B25],[@B29],[@B32]\]
           rs3803012 (A \> G)    3′-UTR          BC, HNC, CC, and HCC                               \[[@B2],[@B36]\]
           rs3809142 (C \> T)    Upstream        BC                                                 \[[@B2]\]
           rs7301722 (C \> A)    Upstream        BC                                                 \[[@B2]\]
           rs7958223 (C \> A)    Intron          BC                                                 \[[@B31]\]
           rs10848236 (G \> A)   Intron          BC                                                 \[[@B31]\]
  DICER1   rs1057035 (T \> C)    3′-UTR          BC                                                 \[[@B2],[@B31]\]
           rs3742330 (A \> G)    3′UTR           PC, LC, and larynx cancer                          \[[@B15],[@B25],[@B39]\]
           rs2282265 (A \> G)    Intron          BC                                                 \[[@B31]\]
           rs13078 (T \> A)      3′-UTR          LC and larynx                                      \[[@B15],[@B25]\]
  TARBP2   rs784567 (A \> G)     5′-UTR          PC and larynx                                      \[[@B25]\]
           rs2280448 (C \> T)    5′-UTR          BC                                                 \[[@B31]\]
  AGO1     rs595055 (G \> A)     Intron          BC                                                 \[[@B31]\]
           rs11263833 (T \> G)   Intron          BC                                                 \[[@B31]\]
           rs636832 (A \> G)     Intron          LC                                                 \[[@B15]\]
           rs595961 (G \> A)     Intron          LC and RCC                                         \[[@B14],[@B15]\]
  AGO2     rs4961280 (A \> C)    Upstream        PC                                                 \[[@B39]\]
           rs77216619 (G/T)      Intron          BC                                                 \[[@B2]\]
           rs78796470 (C \> T)   Intron          BC                                                 \[[@B2]\]
           rs2292779 (G \> C)    Intron          BC                                                 \[[@B31]\]
           rs3864659 (A \> C)    Intron          BC                                                 \[[@B31]\]
           rs7016981 (T \> C)    Intron          BC                                                 \[[@B31]\]
           rs7824304 (C \> T)    Intron          BC                                                 \[[@B31]\]
           rs11786030 (A \> G)   3′-UTR          BC                                                 \[[@B31]\]
  HIWI     rs10773771 (T \> C)   3′-UTR          BC                                                 \[[@B2]\]
           rs4759659 (G \> A)    Intron          BC                                                 \[[@B31]\]
           rs7963072 (G \> A)    Intron          BC                                                 \[[@B31]\]
           rs1106042 (G \> A)    Exon (K527R)    BC and LC                                          \[[@B15],[@B31]\]
           rs11060845 (G \> T)   Intron          BC                                                 \[[@B31]\]
  GEMIN3   rs197414 (C \> A)     Exon (S693R)    PC, BC, and LC                                     \[[@B15]\]
           rs197388 (T \> A)     Upstream        LC                                                 \[[@B15]\]
           rs197412 (T \> C)     Exon (T636I)    LC, RCC, and OC                                    \[[@B14],[@B15],[@B35]\]
           rs11584657 (C \> T)   Upstream        BC                                                 \[[@B2]\]
           rs17504173 (A \> G)   3′-UTR          BC                                                 \[[@B2]\]
           rs197413 (G \> A)     Exon (V642V)    BC                                                 \[[@B31]\]
           rs17569368 (A \> T)   Intron          BC                                                 \[[@B31]\]
  GEMIN4   rs7813 (C \> T)       Exon (C1033R)   PC,BC, LC, and RCC                                 \[[@B14],[@B15],[@B31]\]
           rs3744741 (C \> T)    Exon (R684Q)    BC and LC                                          \[[@B2],[@B15],[@B31]\]
           rs4968104 (T \> A)    Exon (V593E)    BC and LC                                          \[[@B2],[@B15],[@B31]\]
           rs2251689 (G \> A)    Upstream        BC                                                 \[[@B2]\]
           rs2740348 (C \> G)    Exon (E450Q)    BC and LC                                          \[[@B15]\]
           rs910924 (C \> T)     Upstream        LC                                                 \[[@B15]\]
           rs910925 (G \> C)     Exon (G579A)    LC                                                 \[[@B15]\]
           rs1062923 (T \> C)    Exon (T739I)    LC                                                 \[[@B15]\]
           rs2740349 (A \> G)    Exon (N929D)    BC                                                 \[[@B31]\]
  FMR1     rs25704 (T \> C)      3′-UTR          BC                                                 \[[@B31]\]
           rs28900 (A \> C)      Intron          BC                                                 \[[@B31]\]
           rs971000 (C \> T)     Intron          BC                                                 \[[@B31]\]

Abbreviations: BC, breast cancer; CC, cervical cancer; CRC, colorectal cancer; EC, esophageal cancer; GC, gastric cancer; HCC, hepatocellular carcinoma; HNC, head and neck cancer; LC, lung cancer; OC, oral cancer; PC, prostate cancer; RCC, renal cell carcinoma; TC, thyroid cancer.

In summary, we performed a systematic review on the association between *DROSHA* and *DGCR8* polymorphisms and risk of cancer. Meanwhile, all available data were utilized to achieve a meta-analysis for seven prevalent SNPs. Three of them (*DROSHA* rs10719, rs6877842, and *DGCR8* rs417309) were revealed to be associated with risk of cancer in whole population or some particular subgroups. Our study generalized the status quo of the current studies on cancer-related polymorphisms in *DROSHA* and *DGCR8* genes, supplying investigators with novel clues for identifying new biomarkers with cancer-forewarning function.
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